Healthcare spending for the Medicaid expansion population increased steadily over time for beneficiaries who remained enrolled in Medicaid, according to a new analysis from Avalere Health. The analysis also found that spending for prescription drugs increased over the study period, with pharmacy costs (excluding prescription drug claims for hepatitis C treatments) almost doubling over the 2.5-year time period during which the cohort was tracked
Healthcare spending for the Medicaid expansion population increased steadily over time for beneficiaries who remained enrolled in Medicaid, according to a new analysis from Avalere Health. The analysis also found that spending for prescription drugs increased over the study period, with pharmacy costs (excluding prescription drug claims for hepatitis C treatments) almost doubling over the 2.5-year time period during which the cohort was tracked—a likely indication that the previously uninsured population may have had previously untreated conditions, and that gaining access to health insurance helped to provide needed care to these enrollees. The analysis concludes that utilization and costs among Medicaid expansion enrollees will continue to increase, particularly for non-acute-care services, the longer members remain covered.
“Contrary to some expectations that Medicaid expansion enrollees would be relatively healthy, beneficiaries who have remained on the program have increasing healthcare needs, likely due to previously unidentified or untreated conditions,” said report coauthor Caroline Pearson, senior vice president at Avalere.
Across plans, states, and enrollment groups, healthier, younger, lower-cost enrollees appear more likely to drop their enrollment in Medicaid after a shorter period of time, the report found: about half of enrollees dropped coverage within 18 months. There are many factors that could be involved in disenrollment from a Medicaid managed care organization (MCO) plan: enrollees could gain access to employer-sponsored insurance, their income could increase and make them ineligible for Medicaid, or individuals could fail to meet a state’s administrative requirement for eligibility redeterminations.
Avalere’s analysis was performed on claims data from January 2014 through December 2016 from 3 Medicaid MCOs offering coverage in states that expanded Medicaid on January 1, 2014 after the Affordable Care Act (ACA) provided states with the option of extending Medicaid eligibility. Many of these new enrollees were previously uninsured.
The analysis found:
Avalere’s report, “Profile of the Medicaid Expansion Population: Demographics, Enrollment, and Utilization,” was funded by the Anthem Public Policy Institute.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.